Stock RPHM RENEO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Reneo Pharmaceuticals, Inc.

Equities

RPHM

US75974E1038

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
1.81 USD -2.69% Intraday chart for Reneo Pharmaceuticals, Inc. +4.02% +13.12%
May. 07 Reneo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 28 Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
GL
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
GL
North American Morning Briefing : Tech in Focus on -2-
DJ
Concentra Biosciences, LLC submitted a non-binding proposal to acquire Reneo Pharmaceuticals, Inc. for $60 million.
CI
North American Morning Briefing : Stock Futures -2-
DJ
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) added to NASDAQ Biotechnology Index
CI
Ladenburg Thalmann Downgrades Reneo Pharmaceuticals to Neutral From Buy
MT
HC Wainwright Downgrades Reneo Pharmaceuticals to Neutral From Buy, Cuts Price Target to $1.50 From $30
MT
Sector Update: Health Care Stocks Slipping Late Afternoon
MT
Top Midday Decliners
MT
Piper Sandler Downgrades Reneo Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $4 From $25
MT
Sector Update: Health Care Stocks Ease Thursday Afternoon
MT
Reneo Pharmaceuticals Says Pivotal Study of Mavodelpar Fails to Meet Primary, Secondary Endpoints; Shares Plunge
MT
Baird Downgrades Reneo Pharmaceuticals to Neutral From Outperform, Cuts Price Target to $3 From $28
MT
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
GL
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
AQ
William Blair Starts Reneo Pharmaceuticals With Outperform Rating
MT
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RPHM Stock
  4. News Reneo Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW